Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture

Anika Therapeutics, Inc.

2024-Q3 EPS reported -$2.34 revenue$121,197,000

Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).
Integrity Implant System grew 40%+ sequentially, >500 surgeries since launch, Regenerative Solutions up 17%.
Exiting Arthrosurface (sold) and Parcus Medical (divestiture planned) to focus on HA technology and Commercial Channel.
Updated 2024 guidance: Commercial Channel +14% to +19%, OEM -8% to -10%, Adj EBITDA $16-18M; restructuring charges $3-5M cash, $27-29M non-cash.
First Hyalofast PMA module filed Oct 28; Cingal NDA path progress including acquisition of Aristospan NDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.